代表论文 (*通讯作者)：

1. Ma J, He Q, Pu J, Liu Y, Cui X, Wang G, Chen Q, Ren L, Li M, Hou P*. SNORD50A/B disassemble ASC-1 complex to silence NF-κB and boost PD-1 blockade in non-small-cell lung cancer. NPJ Precis Oncol. 2026. (IF: 9.9, Q1）

2. Zhang R, Zong D, Liu R, Wang Y, Gu Q, Yao Y, Zheng W, Yuan M, Wang S, Cui R, Li D, Dang S, Hou P*. TRMT6-Mediated m1A Modification of CDK9 mRNA Is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma. Adv Sci. 2026. (IF: 14.1, Q1）

3. Pu J, Ma J, Liu Y, Cui R, Yao Y, Zhang G, Hou P, Liu X, Yang Q, Ji M. Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma. Exp Mol Med. 2025. (IF: 17.5, Q1）

4. Zhang H, Zeng Z, Liu Y, Zheng W, Wang J, Yao Y, Wang Y, Ji M*, Hou P*. Thyrotropin exacerbates insulin resistance by triggering macrophage inflammation in subclinical hypothyroidism. Exp Mol Med. 2025. (IF: 17.5, Q1）

5. Liu Z, Li Y, Wang S, Wang Y, Sui M, Liu J, Chen P, Wang J, Zhang Y, Dang C, Hou P*. Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. J Exp Clin Cancer Res. 2025 Feb 25;44(1):70. (IF: 14.3, Q1）

6. Yuan M, Shi L, Liu Y, Xiang K, Zhang Y, Zhou Y, Wang J, Ji M, Hou P*. Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade. Int J Biol Sci. 2025 Feb 3;21(4):1730-1748. (IF: 11.7, Q1）

7. Chen Y, Bao Y, Wang Y, Liu J, Zheng W, Chen P, Wei W, Ji M, Zhang R, Hou P*, Chen C*. Alkyl chain engineering of ionic AIE molecules for developing superior self-adjuvanted nanovaccines in cancer immunotherapy. Chemical Engineering Journal. 2025;506;159979. (IF: 13.2, Q1）

8.  Liu J, Zhang R, Bao Y, Chen Y, Zheng W, Yuan J, Zhang Z, Chen P, Ji M, Cheng Y*, Hou P*, Dang D, Ding D, Chen C*. Highly Efficient and Universal Degradation of PD-L1 via Mitochondrial Oxidative Stress Evoked by Cationic AIE-Active Photosensitizers for Cancer Immunotherapy. Adv. Funct. Mater. 2025;35(7). (IF: 19.9, Q1）

9. Liu Y, Yuan M, Xu X, Yang H, Yao Y, Hou P*, Yu W*, Ji M*. USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21. Int J Biol Sci.  2024 23;20(13):5223-5238. (IF: 11.7, Q1)

10. Zhou Y, Wang S, Guo J, Li C, Sui M, Zeng Z, Dang H, Gu Q, Zhu J*, Cheng Y*, Hou P*. Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. J Control Release. 2024; 374:489-504. (IF: 12.4, Q1)

11. Zhang R, Chen P, Wang Y, Zeng Z, Yang H, Li M, Liu X*, Yu W*, Hou P*. Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m(6)A-YTHDF1-dependent manner. Int J Biol Sci. 2024;20(12):4750-66. (IF: 11.7, Q1)

12. Wang S, Sui M, Chen Q, Guo J, Yang H, Zhou Y, Ji M, Cheng Y*, Hou P*. Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy. Chemical Engineering Journal. 2024; 498:155074. (IF: 13.2, Q1)

13. Sui M, Wang S, Zhou Y, Dang H, Zeng Z, Gu K, Cao H, Ji M, Da P*, Cheng Y*, Hou P*. A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis. Chemical Engineering Journal. 2024; 494:153131. (IF: 13.2, Q1)

14. Lan X, Li H, Guo J, Feng C, Zhou X, Wang J, Li D, Ji M, Hou P*, Yang Q*. Lung-targeted delivery of nsp12 siRNAs restores host type I interferon responses. Chemical Engineering Journal. 2024; 491:151973. (IF: 13.2, Q1)

15. Zhang Y, Liang L, Li H, Cao Y, Meng D, Li X, Wang M, Wang J, Yao Y, Zhang S, Chen C*, Hou P*, Yang Q*. Smart multi-functional aggregates reoxygenate tumor microenvironment through a two-pronged strategy to revitalize cancer immunotherapy. Aggregate 2024; 5(4): e545. (IF: 13.7, Q1)

16. Li X, Liu Y, Liu J, Qiang W, Ma J, Xie J, Chen P, Wang Y, Hou P*, Ji M*. STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells. Cell Death Dis. 2023;14(7):454. (IF: 12.2, Q1)

17. Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J, Cao H, Li Y, Ji M*, Hou P*. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. Exp Mol Med. 2023;55(8):1757-1769. (IF: 17.5, Q1)

18. Yang Q, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023;42(20):1634-8. (IF: 9.1, Q1)

19. Wang Y, Chen P, Zhao M, Cao H, Zhao Y, Ji M, Hou P*, Chen M*. EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling. Cell Death Dis. 2022;13(10):910. (IF: 12.2, Q1)

20. Zeng Z, Zheng W, Hou P*. The role of drug-metabolizing enzymes in synthetic lethality of cancer. Pharmacol Ther. 2022;240:108219. (IF: 13.5, Q1)

21. Liu Z, Meng D, Wang J, Cao H, Feng P, Wu S, Wang N, Dang C, Hou P* Xia P. GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to paclitaxel by forming a vicious cycle with IGF1/IGF1R signaling pathway. Cell Death Dis. 2022;13(8):751. (IF: 12.2, Q1) 

22. Ma S, Wang N, Liu R, Zhang R, Dang H, Wang Y, Wang S, Zeng Z, Ji M*, Hou P*. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J Exp Clin Cancer Res. 2021;40(1):387. (IF: 14.3, Q1)

23. Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, Shi B, Yang J*, He N*, Hou P*. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021;6(1):399. (IF: 81.2, Q1)

24. Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, Lan X, Zhao Y, Qiang W, Ji M*, Hou P*. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ. 2021;28(8):2450-2464. (IF: 13.6, Q1)

25.  Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M, Hou P*. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by improving hypoxic tumor microenvironment. J Nanobiotechnology. 2021;19(1):302. (IF: 15.0, Q1)

26. Wu Y, Shi L, Zhao Y, Chen P, Cui R, Ji M, He N, Wang M*, Li G*, Hou P*. Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF V600E-driven human cancers. NPJ Precis Oncol. 2021;5(1):3. (IF: 9.9, Q1)

27. Bai Z, Qu Y, Shi L, Li X, Yang Z, Ji M*, Hou P*. Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype. Cell Death Dis. 2021;12(8):765. (IF: 12.2, Q1)

28. Li Y, Su X, Feng C, Liu S, Guan H, Sun Y, He N*, Ji M*, Hou P*. CYP2S1 is a synthetic lethal target in BRAF V600E-driven thyroid cancers. Signal Transduct Target Ther. 2020;5(1):191. ( IF: 81.2, Q1)

29. He W, Yan J, Li Y, Yan S, Wang S, Hou P*, Lu W*. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics. J Control Release. 2020;325:293-303. (IF: 12,4, Q1)

30. Li M, Ruan B, Wei J, Yang Q, Chen M, Ji M*, Hou P*. ACYP2 contributes to malignant progression of glioma through promoting Ca²⁺ efflux and subsequently activating c-Myc and STAT3 signals. J Exp Clin Cancer Res. 2020;39(1):106. (IF: 14.3, Q1)

31. Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M*, Hou P*. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 2019;9(15):4461-4473. (IF: 14,9, Q1)

32. Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112-124. (IF: 20.3, Q1)

33. He W, Yan J, Wang L, Lei B, Hou P*, Lu W*, Ma PX*. A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties. Biomaterials. 2019;206:13-24. (IF: 13.6, Q1)

34. Liu J, Yan J, Yan S, Wang Y, Zhang R, Hou P, He W*, Ji M*. Biomimetic and self-assembled nanoclusters targeting β-catenin for potent anticancer therapy and enhanced immunotherapy. Nano Lett. 2019;19(12):8708-8715. (IF: 9.1, Q1)

35. He W, Wang S, Yan J, Qu Y, Jin L, Sui F, Li Y, You W, Yang G, Yang Q, Ji M, Liu M, Shao Y, Ma PX*, Lu W*, Hou P*. Self-assembly of therapeutic peptide into stimuli-responsive clustered nanohybrids for cancer-targeted therapy. Adv Funct Mater. 2019;29(10):1807736. (IF: 19.9, Q1)

36. Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019;38(24):4804-4819. (IF: 9.1, Q1)

37. Bian Z, Yan J, Wang S, Li Y, Guo Y, Ma B, Guo H, Lei Z, Yin C, Zhou Y, Liu M, Tao K*, Hou P*, He W*. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery. Theranostics. 2018;8(19):5320-5335. (IF: 14.9, Q1)

38. Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene. 2019;38(3):345-359. (IF: 9.1, Q1)

39. He W*, Yan J, Sui F, Wang S, Su X, Qu Y, Yang Q, Guo H, Ji M, Lu W, Shao Y*, Hou P*. Turning a Luffa protein into a self-assembled biodegradable nanoplatform for multitargeted cancer therapy. ACS Nano. 2018;12(11):11664-11677. (IF: 17.3, Q1)

40. Li Y, Yang Q, Guan H, Shi B, Ji M, Hou P*. ZNF677 is a potent tumor suppressor in thyroid cancer through inhibiting Akt phosphorylation. Cancer Res. 2018;78(18):5216-5228. (IF: 16.6, Q1)

41. Qu Y, Shi B, Hou P*. Activated ERK: An emerging player in miRNA downregulation. Trends in Cancer. 2017;3(3):163-165. (IF: 21.6, Q1)

42. Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G, Hou P*. c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics. 2017; 7(8):2092-2107. (IF: 14.9, Q1)

43. Yang Q and Hou P*. Targeting PFKFB3 in the endothelium for cancer therapy. Trends Mol Med. 2017;23(3):197-200. (IF: 18.1, Q1)

44. Shi J, Qu Y, Li X, Sui F, Yao D, Yang Q, Shi B, Ji M, Hou P*. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis. 2016;7(10):e2442. (IF: 12.2, Q1)

45. Qu Y, Dang S, Hou P*. Gene methylation in gastric cancer. Clin Chim Acta. 2013;424:53-65. (ESI高被引) (IF: 4.1, Q2)

46. Hou P, Liu D, Shan Y, Hu S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161-70.(IF: 10.9, Q1) 

47. Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5'-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003;31(16):e92. (IF: 15.0, Q1)

      其它SCI论文请链接http://www.ncbi.nlm.nih.gov/pubmed/?term=peng+hou